125 related articles for article (PubMed ID: 38072417)
61. Downregulation of Polo-like kinase-1 (PLK-1) expression is associated with poor clinical outcome in uveal melanoma patients.
Berus T; Markiewicz A; Kobylinska K; Biecek P; Orlowska-Heitzman J; Romanowska-Dixon B; Donizy P
Folia Histochem Cytobiol; 2020; 58(2):108-116. PubMed ID: 32602935
[TBL] [Abstract][Full Text] [Related]
62. Putative link between Polo-like kinases (PLKs) and Toll-like receptor (TLR) signaling in transformed and primary human immune cells.
El Maadidi S; Weber ANR; Motshwene P; Schüssler JM; Backes D; Dickhöfer S; Wang H; Liu X; Garcia MD; Taumer C; Soufi B; Wolz OO; Klimosch SN; Franz-Wachtel M; Macek B; Gay NJ
Sci Rep; 2019 Sep; 9(1):13168. PubMed ID: 31511529
[TBL] [Abstract][Full Text] [Related]
63. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.
Svirnovski AI; Shman TV; Serhiyenka TF; Savitski VP; Smolnikova VV; Fedasenka UU
Hematology; 2009 Aug; 14(4):204-12. PubMed ID: 19635183
[TBL] [Abstract][Full Text] [Related]
64. The clinical relevance and prognostic significance of adenosine triphosphate ATP-binding cassette (ABCB5) and multidrug resistance (MDR1) genes expression in acute leukemia: an Egyptian study.
Farawela HM; Khorshied MM; Kassem NM; Kassem HA; Zawam HM
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1323-30. PubMed ID: 24804815
[TBL] [Abstract][Full Text] [Related]
65. Interplay between Polo kinase, LKB1-activated NUAK1 kinase, PP1βMYPT1 phosphatase complex and the SCFβTrCP E3 ubiquitin ligase.
Banerjee S; Zagórska A; Deak M; Campbell DG; Prescott AR; Alessi DR
Biochem J; 2014 Jul; 461(2):233-45. PubMed ID: 24785407
[TBL] [Abstract][Full Text] [Related]
66. Phosphorylation of synucleins by members of the Polo-like kinase family.
Mbefo MK; Paleologou KE; Boucharaba A; Oueslati A; Schell H; Fournier M; Olschewski D; Yin G; Zweckstetter M; Masliah E; Kahle PJ; Hirling H; Lashuel HA
J Biol Chem; 2010 Jan; 285(4):2807-22. PubMed ID: 19889641
[TBL] [Abstract][Full Text] [Related]
67. SKA3 Promotes Cell Growth in Breast Cancer by Inhibiting PLK-1 Protein Degradation.
Ruan LW; Li PP; Jin LP
Technol Cancer Res Treat; 2020; 19():1533033820947488. PubMed ID: 32799774
[TBL] [Abstract][Full Text] [Related]
68. Functional studies on the role of the C-terminal domain of mammalian polo-like kinase.
Jang YJ; Lin CY; Ma S; Erikson RL
Proc Natl Acad Sci U S A; 2002 Feb; 99(4):1984-9. PubMed ID: 11854496
[TBL] [Abstract][Full Text] [Related]
69. pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1.
Benoit DS; Henry SM; Shubin AD; Hoffman AS; Stayton PS
Mol Pharm; 2010 Apr; 7(2):442-55. PubMed ID: 20073508
[TBL] [Abstract][Full Text] [Related]
70. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.
Valdez BC; Nieto Y; Murray D; Li Y; Wang G; Champlin RE; Andersson BS
Exp Hematol; 2012 Oct; 40(10):800-10. PubMed ID: 22687754
[TBL] [Abstract][Full Text] [Related]
71. Regulatory functional territory of PLK-1 and their substrates beyond mitosis.
Kumar S; Sharma G; Chakraborty C; Sharma AR; Kim J
Oncotarget; 2017 Jun; 8(23):37942-37962. PubMed ID: 28415805
[TBL] [Abstract][Full Text] [Related]
72. The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.
Goto S; Goto H; Yokosuka T
Int J Hematol; 2016 May; 103(5):572-83. PubMed ID: 26886449
[TBL] [Abstract][Full Text] [Related]
73. BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA.
Bogeljić Patekar M; Milunović V; Mišura Jakobac K; Perica D; Mandac Rogulj I; Kursar M; Planinc-Peraica A; Ostojić Kolonić S
Acta Clin Croat; 2018 Sep; 57(3):542-553. PubMed ID: 31168188
[TBL] [Abstract][Full Text] [Related]
74. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.
Gaul L; Mandl-Weber S; Baumann P; Emmerich B; Schmidmaier R
J Cancer Res Clin Oncol; 2008 Feb; 134(2):245-53. PubMed ID: 17653574
[TBL] [Abstract][Full Text] [Related]
75. Long-term safety experience with bendamustine for injection in a real-world setting.
Martin P; Barr PM; James L; Pathak A; Kahl B
Expert Opin Drug Saf; 2017 Jun; 16(6):647-650. PubMed ID: 28395515
[TBL] [Abstract][Full Text] [Related]
76. A polo-like kinase modulates cytokinesis and flagella biogenesis in Giardia lamblia.
Park EA; Kim J; Shin MY; Park SJ
Parasit Vectors; 2021 Mar; 14(1):182. PubMed ID: 33789729
[TBL] [Abstract][Full Text] [Related]
77. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D
Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728
[TBL] [Abstract][Full Text] [Related]
78. SmSak, the second Polo-like kinase of the helminth parasite Schistosoma mansoni: conserved and unexpected roles in meiosis.
Long T; Vanderstraete M; Cailliau K; Morel M; Lescuyer A; Gouignard N; Grevelding CG; Browaeys E; Dissous C
PLoS One; 2012; 7(6):e40045. PubMed ID: 22768216
[TBL] [Abstract][Full Text] [Related]
79. Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian polo-like kinase.
Jang YJ; Ma S; Terada Y; Erikson RL
J Biol Chem; 2002 Nov; 277(46):44115-20. PubMed ID: 12207013
[TBL] [Abstract][Full Text] [Related]
80. Polo-like kinases and acute leukemia.
Goroshchuk O; Kolosenko I; Vidarsdottir L; Azimi A; Palm-Apergi C
Oncogene; 2019 Jan; 38(1):1-16. PubMed ID: 30104712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
